Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $45.6 Million - $51.3 Million
-251,860 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $2.07 Million - $2.41 Million
-11,591 Reduced 4.4%
251,860 $49 Million
Q3 2018

Nov 14, 2018

BUY
$185.29 - $208.89 $51,695 - $58,280
279 Added 0.11%
263,451 $54.6 Million
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $19,926 - $22,381
-120 Reduced 0.05%
263,172 $48.6 Million
Q1 2018

May 15, 2018

SELL
$169.43 - $198.0 $6.22 Million - $7.27 Million
-36,734 Reduced 12.24%
263,292 $44.9 Million
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $6,582 - $7,355
39 Added 0.01%
300,026 $52.2 Million
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $50.2 Million - $57.3 Million
299,987
299,987 $55.9 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Orbis Allan Gray LTD Portfolio

Follow Orbis Allan Gray LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbis Allan Gray LTD, based on Form 13F filings with the SEC.

News

Stay updated on Orbis Allan Gray LTD with notifications on news.